USPs that matters:

New: Defence-ETF Themefolio

Advanced IPO-Section: Equities & ETF (link)

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

IPO InfoDataHub

Short Selling Radar

Powerful & free of charge: Tools 4 WebMaster ...

Tipp: Exclusive Newswire Digest

Info-Hub

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

Campus

KnowHow & Education
Advanced Event Calendar Feed
Mentoring & Coaches

Press

FAQ

What's New

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Home
Terminal
Apontis Pharma AG

Apontis Pharma AG

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

D0R2J8105

SEDOL

N/A

CIK

N/A

apontis-pharma.de

LEI: 894500ETO1J6MR8PDF91

New: Infographics X-Lab

FIGI: BBG0107RVJ41

APPH

Apontis Pharma AG

GICS: - · Sector: EQTY · Sub-Sector: -

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Apontis Pharma

Click to initiate

ENTERPRISE

You are not logged in. Don't worry! Click here and see what Perplexity AI knows about $APPH.

NAME

Apontis Pharma AG

ISIN

DE000A3CMGM5

TICKER

APPH

MIC

XETR

REUTERS

APPH.DE

BLOOMBERG

APPH GR

F&G: 77

24.224,87 DAX · 17,28 Vola-Index · 120.188,61 BTC · 1,16669 EURUSD

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading

Knock out & Barriers (IG)

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Fri, 13.06.2025

Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40 Monheim / Rhein, 13 June 2025. APONTIS PHARMA AG announces that Zentiva AG submitted a specified request (konkretisiertes Verlangen) to the APONTIS PHARMA AG management board, pu...

Research & Analysis

Thu, 15.05.2025

APONTIS PHARMA publishes results for the first quarter of 2025 and confirms forecast for 2025 Group sales rise to EUR 12.9 million in Q1 2025 (3M 2024: EUR 10.0 million) Single Pill combinations grew strongly overall by EUR 0.6 million. The portfolio more than compensated for the tender-related decline of EUR 1.0 million at Tonotec. Further im...

Research & Analysis

Mon, 31.03.2025

APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned Sales increases significantly to EUR 48.5 million in 2024 financial year (2023: EUR 37.0 million) Strong increase in Single Pill combination revenues to EUR 34.4 million (2023: EUR 25.6 million) EBITDA increases by EUR 16.8 mill...

Research & Analysis

Wed, 05.03.2025

Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger squeeze-out of the minority shareholders of APONTIS PHARMA AG – merger agreement planned Monheim / Rhein, 5 March 2025. Zentiva AG today submitted a formal request to APONTIS PHARMA ...

Research & Analysis

Thu, 07.11.2024

APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted Revenue growth for Single Pill combinations in 9M 2024 to EUR 26.2 million (9M 2023: EUR 17.9 million) Novartis collaboration (asthma products) contributes EUR 5.6 million to revenues EBITDA rises to EUR 2.7 million (9M 2023: EUR ...

Research & Analysis

Wed, 30.10.2024

Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer Joint reasoned statement by Management Board and Supervisory Board published Offer price of EUR 10.00 per share represents an attractive premium of around 52.9% compared to the closing price on 15 October 2024 and a premium of 38.3% com...

Research & Analysis

Wed, 16.10.2024

APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer APONTIS PHARMA and Zentiva signed an investment agreement today Growth strategy of APONTIS PHARMA to be continued together with Zentiva APONTIS PHARMA to benefit from the European footprint, the existing research and ...

Research & Analysis

Wed, 16.10.2024

Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer Monheim / Rhein, 16 October 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5), Zentiva Pharma GmbH...

Research & Analysis

Fri, 16.08.2024

Original-Research: APONTIS PHARMA AG - from First Berlin Equity Research GmbH 16.08.2024 / 10:41 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclu...

Research & Analysis

Fri, 09.08.2024

APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed Revenue growth for Single Pill combinations in the first half of 2024 to EUR 17.9 million (H1 2023: EUR 12.1 million), also due to a competitor’s temporary inability to deliver in first quarter of 2024 New ...

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

BARRISTA SMART * AD

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 27.262 Visitors - 22.394 Registered members - 15 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Congratulation France

celebrating National Holiday

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Visual Sitemap

Helpdesk

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Consumer information

Imprint

smart.AD